awmsg logo



ciprofloxacin/fluocinolone (Cetraxal Plus®)


Reference No. 4063

Publication date:
01/04/2019


Appraisal information

ciprofloxacin/fluocinolone (Cetraxal Plus®) 3 mg per ml/0.25 mg per ml ear drops


Company: Aspire Pharma Ltd
BNF category: Ear, nose and oropharynx
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 28/03/2019

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, ciprofloxacin/fluocinolone (Cetraxal Plus®) cannot be endorsed for use within NHS Wales for the treatment in adults and in children aged 6 months and older for the following infections: Acute otitis externa (AOE); Acute otitis media in patients with tympanostomy tubes (AOMT) caused by ciprofloxacin susceptible microorganisms
Statement of Advice (SOA)
Download